- Reducing Scope 3 emissions
- Increasing the percentage of suppliers undergoing ESG assessments
- Reducing groundwater intensity
Mankind Pharma Limited
Greenhouse gas emissions & sustainability report data
In its 2023-2024 reporting, Mankind Pharma Limited disclosed greenhouse gas emissions of 23.3K MT CO2e (Scope 1 & 2). By scope: Scope 1: 6.0K MT CO2e; Scope 2: 17.3K MT CO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
23.3K MT CO2e (Scope 1 & 2)
2023-2024
Renewable Energy
53.17%
of total energy
Water Usage
374.2K KL
2023-2024
Waste
10.0K MT
2023-2024
Energy Use
385.2K GJ
2023-2024
📊 Emissions by Scope (2023-2024)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 6.0K MT CO2e |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 17.3K MT CO2e |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced energy consumption by 1400 MWh/lakh of tablets through energy efficiency initiatives.
- Achieved 53.17% renewable energy share in total energy consumption.
- Recycled and reused 45% of wastewater.
- Recovered, recycled, and reused 85% of solvent in API manufacturing.
- Collected and recycled 100% of post-consumer plastic waste (8008 MT).
🎯 Climate & Sustainability Targets
🔜 Short-term
- Divert 70% of hazardous waste for co-processing by 2027.
📅 Medium-term
- 100% renewable power by 2030.
- Carbon neutral by 2030 (over the base year FY’21).
🌱 ESG Focus Areas
GovernanceEnvironmentSocial